Information about Thiotepa
Liver safety of Thiotepa
Thiotepa therapy has been associated with low rates of serum enzyme elevations during therapy and very rare instances of acute, clinically apparent injury.
Mechanism of action of Thiotepa
Thiotepa (thye' oh tep' a) is an ethylenimine similar in structure and activity to altretamine and is believed to act as an alkylating agent. The alkylating agents act by causing modification and cross linking of DNA, thus inhibiting DNA, RNA and protein synthesis and causing programmed cell death (apoptosis) in rapidly dividing cells.
FDA approval information for Thiotepa
Thiotepa was approved for use in the United States in 1959. Current indications include ovarian and breast cancer and Hodgkin disease. Thiotepa is also administered locally for bladder cancer, neoplastic effusions and malignant meningeal neoplasms.
Dosage and administration for Thiotepa
Thiotepa is available generically in vials of 15 mg. The dose recommended doses varies by indications, route of administration, and body weight.
Side effects of Thiotepa